<DOC>
	<DOCNO>NCT01195246</DOCNO>
	<brief_summary>The purpose study compare immune response HEPLISAV™ booster injection immune response Engerix-B® Fendrix® booster vaccination among patient end stage renal disease ( ESRD ) hemodialysis .</brief_summary>
	<brief_title>Safety Immunogenicity HEPLISAV™ Hepatitis B Virus Vaccine Adults Hemodialysis</brief_title>
	<detailed_description>The immune response HEPLISAV compare Engerix-B Fendrix measure seroprotection rate ( SPR ) 4 week booster injection</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>≥ 18 year age Has loss renal function receive hemodialysis treatment Is seroprotected hepatitis B ( antiHBs &lt; 10 mIU/mL ) In opinion investigator , clinically stable Be serum negative HBsAg , antihepatitis B core antigen ( HBc ) , hepatitis C virus ( HCV ) , HIV Is schedule undergo kidney transplant study period If female , childbearing potential , subject must : surgically sterile neither pregnant breastfeeding , consistently use highly effective method birth control least one month prior study entry , agree use two form birth control consistently throughout study . If female , pregnant , breastfeeding , plan pregnancy ; Has history high risk recent exposure HBV , HCV , HIV ; Has know history autoimmune disease ; Has history sensitivity component study vaccine ; Has current condition renal disease substance alcohol abuse would interfere compliance interpretation study result ; Is undergo chemotherapy expect receive chemotherapy study period ; diagnosis cancer within last 5 year squamous basal cell carcinoma skin ; Has uncontrolled diabetes ; Has receive kidney transplant previously still function require antirejection medication ; Has receive blood product immunoglobulin within 3 month prior study entry , likely require infusion blood product study period ; Has receive follow prior study injection : 3 day : intravenous iron ; 21 day : inactivate virus bacterial vaccine ; 28 day : live virus bacterial vaccine ; systemic corticosteroid ( 3 consecutive day ) immunomodulators immune suppressive medication , exception inhale steroid ; granulocyte colony stimulate factor ( GCSF ) granulocytemacrophage colony stimulate factor ( GMCSF ) ; investigational medicinal agent ; At time : injection deoxyribonucleic acid ( DNA ) plasmids oligonucleotides ; investigational intradermal hepatitis B vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>end stage renal failure</keyword>
	<keyword>renal failure</keyword>
	<keyword>kidney failure</keyword>
	<keyword>kidney failure , chronic</keyword>
	<keyword>chronic kidney failure</keyword>
	<keyword>hepatitis B virus ( HBV ) vaccine</keyword>
	<keyword>hepatitis B vaccine</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>hepatitis</keyword>
	<keyword>HBV</keyword>
	<keyword>prevention control</keyword>
	<keyword>dialysis</keyword>
</DOC>